financetom
Business
financetom
/
Business
/
PayPal forecasts 2025 profit above estimates as turnaround gains traction
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
PayPal forecasts 2025 profit above estimates as turnaround gains traction
Feb 4, 2025 4:32 AM

Feb 4 (Reuters) - PayPal ( PYPL ) forecast full-year

profit above estimates on Tuesday, fueled by the digital

payments giant's push to revive growth in branded products,

improve pricing and sharpen cost-cutting efforts.

Since taking over in late 2023, PayPal ( PYPL ) CEO Alex Chriss has

focused on high-margin products and touted 'profitable growth'

as the company's new strategy. PayPal ( PYPL ) has since revamped its

pricing approach and shifted away from chasing revenue

acceleration.

The upbeat outlook will likely ease investor worries about

increasing competition from big-tech giants and fintech rivals

such as Block in the digital payments sector.

PayPal ( PYPL ) has worked to defend its dominant position with new

products, including a "one-click" checkout feature called

Fastlane, and forged lucrative partnerships with companies such

as Global Payments ( GPN ) and Fiserv ( FI ).

Transaction margin dollars, a key measure of the

profitability of its core business, increased 7% for the full

year.

"The improvements we made to branded checkout, peer-to-peer,

and Venmo, plus the progress we made on our price-to-value

strategy, are beginning to show up in our results," Chriss said.

PayPal ( PYPL ) expects full-year adjusted profit to grow between

$4.95 and $5.10 per share, surpassing Wall Street views of $4.90

according to estimates compiled by LSEG.

It expects transaction margin dollars to grow between 4% and

5% in 2025.

SPENDING RESILIENT DESPITE CHALLENGES

Stronger margins and profitability in branded checkout

products, which includes PayPal's ( PYPL ) core payment services,

headlined 2024 for the payments company after years of uneven

results.

Consumer spending has also remained resilient as Americans

brush off concerns over high interest rates and shrinking

savings, splurging on everything from travel to online shopping.

Analysts and investors are optimistic about the outlook for

the payments sector this year, though the recent imposition of

tariffs by the U.S. President Donald Trump's administration on

China are seen as potentially inflationary.

For the first quarter, PayPal ( PYPL ) expects to post an adjusted

profit in the range $1.15 to $1.17 per share, above expectations

of $1.14.

The holiday season also lured shoppers as retailers offered

deep discounts on Christmas, Thanksgiving, Black Friday and

Cyber Monday.

PayPal's ( PYPL ) net revenue increased 4% to $8.4 billion in the

fourth quarter ended Dec. 31. Total payment volume climbed 7%,

mirroring results at traditional card networks - Visa and

Mastercard ( MA ).

It posted a fourth-quarter adjusted profit of $1.19, topping

estimates of $1.12.

PayPal's ( PYPL ) shares surged nearly 40% in 2024, outperforming

broader markets and ending three years of consecutive annual

declines.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment
Jun 18, 2024
11:40 AM EDT, 06/18/2024 (MT Newswires) -- Immunocore Holdings ( IMCR ) said Tuesday it has randomized the first patient in a phase 3 clinical trial of brenetafusp in combination with nivolumab to treat first-line advanced or metastatic cutaneous melanoma, a type of skin cancer. The trial will randomize patients with first-line advanced or metastatic cutaneous melanoma to brenetafusp plus...
What's Going On With Mustang Bio Stock Tuesday?
What's Going On With Mustang Bio Stock Tuesday?
Jun 18, 2024
Mustang Bio, Inc. ( MBIO ) shares appear to be trending upward Tuesday on continued momentum after the company on Monday announced safety and efficacy data from its Phase 1/2 clinical trial of MB-106, a possible treatment for certain types of blood cancer. 90% of patients treated with MB-106 responded to the treatment with three complete responses. Out of the...
Lexaria Bioscience Hires Contract Research Organization For 12-week Study
Lexaria Bioscience Hires Contract Research Organization For 12-week Study
Jun 18, 2024
11:40 AM EDT, 06/18/2024 (MT Newswires) -- Lexaria Bioscience ( LEXX ) said Tuesday that it hired a contract research organization to manage its 12-week chronic study, GLP-1-H24-4, to evaluate different DehydraTECH-GLP-1 formulations and other treatments, focusing on goals such as weight loss and reducing blood sugar levels. Preparations for the study with the CRO have started under an initial...
What's Going On With Greenwave Technology
What's Going On With Greenwave Technology
Jun 18, 2024
Greenwave Technology Solutions, Inc. ( GWAV ) shares are trading higher Tuesday after the company announced the completion of its recapitalization. The Details: Greenwave said it has strengthened its balance sheet by approximately $80.5 million since February and has a current cash balance of over $26 million, its strongest cash position in company history.  The company also said it is...
Copyright 2023-2025 - www.financetom.com All Rights Reserved